Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Weight-Bearing CT’s Role in Assessing Pes Cavovarus

Dr. Alessio Bernasconi, MD, FEBOT and  his colleagues at the Royal National Orthopaedic Hospital in London have produced critical and salient findings about the role of weight-bearing CT imaging (WBCT) in assessing pes cavovarus. Dr. Bernasconi recently shared these findings in a FOOTinnovate webinar, and his presentation is outlined below. Click here to watch the FOOTInnovate…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Dr. Alessio Bernasconi, MD, FEBOT and his colleagues at the Royal National Orthopaedic Hospital in London have produced critical and salient findings about the role of weight-bearing CT imaging (WBCT) in assessing pes cavovarus.

Dr. Bernasconi recently shared these findings in a FOOTinnovate webinar, and his presentation is outlined below.

Click here to watch the FOOTInnovate webinar. A FOOTInnovate account is required.

A Refresher on Pes Cavovarus Diagnosing Procedures

Pes cavovarus is considered a three-dimensional deformity and is characterized by a high-arched, varus hindfoot alignment with a forefoot that may be abducted or plantarflexed depending on the individual case.

Diagnostic work for pes cavovarus is based on a thorough clinical assessment. However, additional imaging is needed, and X-Ray imaging is the current standard. Additional CT or MRI imaging can be ordered to further characterize the deformity and assess the status of joints and soft tissues.

However, common dorsoplantar, lateral views of bilateral cavovarus deformity can bring along with them difficulty in precisely identifying joint planes and status. Recent studies, including published papers from PubMed suggest that radiographs have inherent bias as beam position, operators, foot position, and more can change what doctors see and identify.

Is there any objective way to identify hindfoot alignment?

Improving Identification of Hindfoot Alignment

The Saltzman view – developed by Charles Saltzman, MD and Georges El-Khoury, MD – is designed to find the main axis of the tibia and the main axis of the calcaneus, then to define the angle between those two lines.

However, this view can still be limited by rotation of the foot.

That’s why authors like Jonathan Kaplan, MD, who outlined a solution in Foot & Ankle International, propose the use of weight-bearing CT scanning as a better alternative when diagnosing malalignment associated with pes cavovarus.

The Implications of Weight-Bearing CT Scanning

Two studies published in 2017 and 2018 introduced the idea of using three-dimensional measurements on weight-bearing CT images, allowing the measurement of malalignment to move away from a single plane and toward a volume-based view that produces a more reliable and true view of the bones in physical space.

The three measurements proposed are foot and ankle offsets, the calcaneal offset and the hindfoot alignment angle.

In 2017, a study assessing 135 datasets including normally aligned feet, varus hindfeet and valgus hindfeet demonstrated excellent inter and intra-observer reliability using this new measurement.

The true revolution in utilizing 3D measurements is that, in gathering the three measurements, you can add a fourth point to represent volume that provides that additional beneficial depth.

“What you need is a cone-beam, weight-bearing CT device,” Dr. Bernasconi said. “In our institution, we use the PedCAT one. You need a software to elaborate data – CubeVue – and you need a TALAS plug-in.”

Essentially, Dr. Bernasconi said, this landmark software solution can provide a simpler way to obtain values relative to the normative values that highlight varus or valgus malalignment.

Critical Questions

Dr. Bernasconi highlighted three critical questions regarding the reliability of this new solution:

  • How reliable are 3D measurements when diagnosing pes cavovarus?
  • Does etiology affect reliability?
  • Does the severity of the deformity affect reliability?

To find the answers, Dr. Bernasconi and the staff at the Royal National Orthopaedic Hospital completed a retrospective study based on STROBE guidelines of patients with a pes cavovarus diagnosis from their hospital between 2015 and 2017.

Eventually settling on 17 patients, the team matched those patients with an equal number of normally aligned feet. Three observers with different levels of expertise and different knowledge of the weight-bearing CT imaging process produced excellent inter-observer reliability. Further, there was little variance between the observers, suggesting that the data is reliable regardless of previous expertise, etiology and deformity severity.

“The reason that we have studied foot morphology, thanks to the help, obviously, of this new technology, (is that) standing CT allows you to reproduce in a more faithful way the true geometry of the bone and the joints in the space,” Dr. Bernasconi said. “We think that this may potentially help us better understand the etiology.”

Though Dr. Bernasconi said his findings were far from enough to fully corroborate this positive outcome, they are certainly a starting point.

The takeaway, he said, is that this new, 3D approach will allow for reliable assessment of pes cavovarus, both in the diagnosing stage and in monitoring patients after procedures to determine how successful the correction was.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512